NASDAQ$RCEL
AVITA Medical Inc · Q1 2026 earnings
Q1 2026 earnings · · After market close · Investor relations
Briefing
AVITA Medical reported modest revenue growth and a narrower net loss for Q1 2026.
Total revenue rose 4% to $19.3 million driven by commercial sales of RECELL and new wound care products. Gross margin was 81.7% while operating expenses declined 11%, resulting in a net loss of $10.6 million versus $13.9 million a year earlier. The company closed a new $60 million credit facility and maintained a cash position of $14.3 million including marketable securities.
- Commercial revenue increased 4% year-over-year to $19.2 million, led by RECELL and contributions from Cohealyx.
- Gross profit margin held at 81.7% with RECELL-only margin at 85.0%.
- Operating expenses fell 11% to $24.5 million through cost discipline and lower headcount.
- Net loss narrowed 23% to $10.6 million as the company refinanced debt with a new $60 million facility.
Headline financials
Revenue & EPS history
AVITA Medical · Revenue · Quarterly
$19.3M
Revenue by segment
AVITA Medical · $19.3M total across 2 segments · Q1 2026
- Sales Revenue$19.1M—99.0%
- Lease Revenue$187K—1.0%
Forward guidance
Management continues to focus on revenue growth, operating leverage, and achieving positive cash flow while maintaining minimum cash covenants under the new credit facility.
Tailwinds
- New $60 million credit facility provides additional liquidity runway.
- All MAC reimbursement rates now published supporting normalized RECELL utilization.
- Positive interim Cohealyx clinical data supports future adoption.
Headwinds
- Substantial doubt remains about going-concern status due to recurring losses.
- TTM revenue covenants must be met to avoid default risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+3.8%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+2.2%
Avg return
30 days after
57%
17 / 30 earnings
Positive
+36.7%
Q4 2022
Best reaction
-25.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.4% | -0.5% | — | |
| Q4 2025 | +11.8% | +15.9% | +18.3% | |
| Q3 2025 | +10.6% | +11.2% | +2.9% | |
| Q2 2025 | -21.2% | +7.1% | -20.8% | |
| Q1 2025 | -25.1% | -28.3% | -34.5% | |
| Q4 2024 | +20.4% | +16.4% | -2.6% | |
| Q3 2024 | -2.0% | +3.9% | +7.3% | |
| Q2 2024 | +19.6% | +20.1% | +10.5% | |
| Q1 2024 | +5.6% | +0.1% | +7.1% | |
| Q4 2023 | -1.7% | +5.2% | -9.8% | |
| Q3 2023 | +9.2% | +29.9% | +32.0% | |
| Q2 2023 | +2.5% | -2.1% | -12.0% | |
| Q1 2023 | -24.5% | -24.2% | +6.8% | |
| Q4 2022 | +36.7% | +48.2% | +41.9% | |
| Q3 2022 | +28.9% | +39.0% | +22.1% | |
| Q2 2022 | -7.1% | -8.7% | -17.8% | |
| Q1 2022 | +9.4% | +10.1% | +8.6% | |
| Q4 2021 | +17.1% | +8.2% | -5.2% | |
| Q3 2021 | +3.5% | -10.7% | -4.6% | |
| Q3 2020 | +3.5% | -10.7% | -4.6% | |
| Q2 2021 | -4.1% | -5.3% | -15.0% | |
| Q1 2021 | -5.4% | -6.4% | -9.6% | |
| Q1 2020 | -5.4% | -6.4% | -9.6% | |
| Q2 2020 | +10.2% | +5.8% | -0.8% | |
| Q1 2019 | +10.2% | +9.5% | +6.2% | |
| Q4 2020 | +10.2% | +9.5% | +6.2% | |
| Q3 2019 | +10.2% | +9.5% | +6.2% | |
| Q4 2018 | -2.5% | -1.9% | +11.4% | |
| Q2 2019 | -2.5% | -1.9% | +11.4% | |
| Q4 2019 | -2.5% | -1.9% | +11.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro